WuXi Biologics (2269)

53.10
-1.95(-3.54%)
  • Volume:
    32,081,710
  • Bid/Ask:
    53.05/53.10
  • Day's Range:
    52.10 - 56.40

2269 Overview

Prev. Close
55.05
Day's Range
52.1-56.4
Revenue
16.02B
Open
53.55
52 wk Range
35-105.7
EPS
0.975
Volume
32,081,710
Market Cap
182.92B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
35,923,589
P/E Ratio
44.59
Beta
0.888
1-Year Change
-46.66%
Shares Outstanding
4,219,568,221
Next Earnings Date
-
What is your sentiment on WuXi Biologics?
or
Market is currently closed. Voting is open during market hours.

WuXi Biologics Analysis

WuXi Biologics Company Profile

WuXi Biologics Company Profile

Employees
10593
Market
Hong Kong

WuXi Biologics (Cayman) Inc. provides end-to-end solutions and services for biologics discovery, development and manufacturing in the People’s Republic of China, North America, Europe, and internationally. The company also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, and biologics clinical and manufacturing services; production and sale of medicals; vaccine CDMO and related business; and material supplier activities. WuXi Biologics (Cayman) Inc. has strategic partnership with ImmuneOncia Therapeutics, Legochem Biosciences Inc, Worg Pharma, OncoC4, and Exelixis Inc. The company was incorporated in 2014 and is headquartered in Wuxi, China.

Read More

Analyst Price Target

Average103.65 (+95.20% Upside)
High200
Low45
Price53.1
No. of Analysts27
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyBuyBuyBuyNeutral
Technical IndicatorsStrong BuyStrong BuyStrong SellStrong BuyStrong Sell
SummaryStrong BuyStrong BuyNeutralStrong BuySell
  • Nomura Axes WUXI BIO TP to $95.75, Rating Buy
    0
    • What’s happen?
      0
      • M Stanley Foresees WUXI BIO Shr Rise in 30 Days, Rated Overweight with $175 TP
        0
        • Daiwa Adds WUXI BIO TP to $167; Rated*** ***Buy
          0
          • C Suisse Hikes WUXI BIO TP to $158, Rated ***Outperform***
            0
            • Goldman Sachs Increases TP to $131.4 Rated BUY ! 👍🏻
              0
              • JPM Hikes WUXI BIO TP to $130; Rated ***Overweight***
                0
                • Nomura Chops WUXI BIO TP to $116.8, Rated ***Buy***
                  1
                  • Definitely will back to 120 by end of this year. Company future is very good. Next factory to be setup to increase capacity expansion is ongoing till 2023. Stay tune for the extraordinary earning in the coning years. Surely a high growth positive cashflow company in China 👍🏻
                    0
                    • Daiwa: WUXI BIO ( Share Correction Overdone Entails Bottom-fish Odds, Restated ***Buy***
                      0